论文部分内容阅读
目的探讨胺碘酮治疗心衰并发房颤的临床疗效及安全性。方法将我院2009年10月到2010年11月收治的60例心衰并发房颤患者随机分为对照组与观察组,每组30例,对照组给予去乙酰毛花苷治疗;观察组给予胺碘酮治疗,比较两组治疗后的心室率、转复窦性心律情况、临床疗效及不良反应发生率。结果观察组的显效率和有效率明显高于对照组(P<0.05);观察组用药24h后的心室率为明显低于对照组(P<0.05);观察组的转复率高于对照组(P<0.05),平均转复时间短于对照组(P<0.05);观察组的不良反应发生率低于对照组(P<0.05)。结论胺碘酮治疗心衰并发房颤的临床疗效优于去乙酰毛花苷,且不良反应少,值得推广使用。
Objective To investigate the clinical efficacy and safety of amiodarone in the treatment of heart failure complicated with atrial fibrillation. Methods Sixty patients with heart failure and atrial fibrillation who were treated in our hospital from October 2009 to November 2010 were randomly divided into control group and observation group, with 30 cases in each group. The control group was given stilbene treatment. The observation group was given Amiodarone treatment, ventricular rate after treatment, ventricular sinus rhythm recovery, clinical efficacy and incidence of adverse reactions. Results The markedly effective rate and effective rate in the observation group were significantly higher than those in the control group (P <0.05). The ventricular rate in the observation group was significantly lower than that in the control group (P <0.05), and the recovery rate in the observation group was higher than that in the control group (P <0.05). The mean recovery time was shorter than that of the control group (P <0.05). The incidence of adverse reactions in the observation group was lower than that of the control group (P <0.05). Conclusions The clinical efficacy of amiodarone in the treatment of heart failure complicated with atrial fibrillation is superior to that of diacetylthioglucoside with less adverse reactions and is worth promoting.